BioCentury
ARTICLE | Clinical News

LJPC-401: Phase I data

September 19, 2016 7:00 AM UTC

An open-label, dose-escalation Phase I trial in 15 patients at risk of iron overload showed that single doses of 1-20 mg subcutaneous LJPC-401 dose-dependently and significantly reduced mean serum iro...